Advertisement
Advertisement

CDXS

CDXS logo

Codexis, Inc.

1.67
USD
Sponsored
-0.08
-4.86%
Mar 26, 14:19 UTC -4
Open

CDXS Earnings Reports

Positive Surprise Ratio

CDXS beat 26 of 41 last estimates.

63%

Next Report

Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
$15.03M
/
-$0.17
Implied change from Q4 25 (Revenue/ EPS)
-61.37%
/
-254.55%
Implied change from Q1 25 (Revenue/ EPS)
+99.27%
/
-32.00%

Codexis, Inc. earnings per share and revenue

On Mar 11, 2026, CDXS reported earnings of 0.11 USD per share (EPS) for Q4 25, beating the estimate of -0.04 USD, resulting in a 357.01% surprise. Revenue reached 38.91 million, compared to an expected 36.55 million, with a 6.47% difference. The market reacted with a +34.65% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.17 USD, with revenue projected to reach 15.03 million USD, implying an decrease of -254.55% EPS, and decrease of -61.37% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
logo
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
logo
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
logo
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
logo
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
logo
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
logo
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
logo
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
logo
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
logo
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
For Q4 2025, Codexis, Inc. reported EPS of $0.11, beating estimates by 357.01%, and revenue of $38.91M, 6.47% above expectations.
The stock price moved up 34.65%, changed from $1.27 before the earnings release to $1.71 the day after.
The next earning report is scheduled for May 12, 2026.
Based on 7 analysts, Codexis, Inc. is expected to report EPS of -$0.17 and revenue of $15.03M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement